Published in Biotech Business Week, January 1st, 2007
This trend article about Louisiana State University, U.S., is an immediate alert from NewsRx to identify developing directions of research.
According to recent research from the United States, "The development of nucleoside analogues has had a major impact on cancer therapy. CS-682 is a novel, orally administered nucleoside analogue with a unique mechanism of action."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.